BBIO Stock — BridgeBio Pharma Inc.: Cash, EV, Pipeline

Share price

$66.61

Market cap

$13,021.4M

Cash

$720.2M

Enterprise value

$14,954.1M

Balance sheet

Cash	$720.2M
Debt	$2,652.9M
Net cash	-$1,932.7M
Enterprise value	$14,954.1M
Basic shares	195.3M shares
Fully diluted shares	254.2M shares
Fully diluted market cap	$16,931.7M
Cash per share	$3.69

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading BBIO daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Aug 12 - Sep 23	AG10	Phase 2	Amyloid Cardiomyopathy	—
Feb 12 - Mar 25	Encaleret	Phase 3	Hypoparathyroidism; Chronic Hypoparathyroidism	—
May 27 - Jul 8	Acoramidis (AG10)	Phase 3	Amyloid Cardiomyopathy, Transthyretin-Related	—
Jan 12 - Feb 23	Encaleret	Phase 3	Autosomal Dominant Hypocalcemia Type 1 (ADH1)	—
Nov 12 - Dec 24	Acoramidis	Phase 3	Amyloidosis; Amyloid Cardiomyopathy; Transthyretin Amyloidosis	—
Jan 12 - Feb 23	Infigratinib	Phase 2	Achondroplasia	—
Jul 12 - Aug 23	Infigratinib	Phase 2	Hypochondroplasia	2H 2026
Dec 13, 2037 - Jan 24, 2038	Acoramidis (AG10)	Phase 3	Amyloidosis in Transthyretin (TTR); Amyloidosis, Familial; Amyloid Cardiomyopathy	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Attruby

Approved · Active Modality: oral small molecule

Aliases AG10, Beyonttra

Target TTR (transthyretin)

Indications

ATTR cardiomyopathy (ATTR-CM) (Approved)

Status note Next-generation oral small molecule near-complete TTR stabilizer. FDA approved November 22, 2024 for cardiomyopathy of wild-type or variant ATTR amyloidosis; EC approved February 10, 2025 (as Beyonttra) for ATTR-CM.

BBP-418

Phase 3 · Active Modality: oral small molecule

Target FKRP

Indications

limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) (Phase 3)

Catalysts

— November 27, 2026

Status note NDA submitted to FDA March 30, 2026; accepted with Priority Review. Designed to supply supra-physiological levels upstream to drive residual activity of the mutant FKRP enzyme.

encaleret

Phase 3 · Active Modality: oral small molecule

Target CaSR (calcium-sensing receptor)

Indications

autosomal dominant hypocalcemia type 1 (ADH1) (Phase 3)
chronic hypoparathyroidism (CHP) (Stage not disclosed)

Catalysts

— May 8, 2027

Status note Negative allosteric modulator of the calcium-sensing receptor. NDA submitted to FDA May 12, 2026 and accepted for filing.

low-dose infigratinib

Phase 3 · Active Modality: oral small molecule

Target FGFR1-3

Indications

achondroplasia (Phase 3)
hypochondroplasia (Phase 3)

Status note Selective FGFR1-3 tyrosine kinase inhibitor; gain-of-function FGFR3 mutations cause achondroplasia/hypochondroplasia. NDA submitted to FDA for achondroplasia; ongoing Phase 2 and Phase 3 trials.

BBP-812

Phase 1 · Active Modality: gene therapy (IV AAV9)

Indications

Canavan disease (Phase 1)

Status note Phase 1/2 CANaspire study ongoing; designed as a single registrational study using a biomarker for accelerated approval. Orphan, Fast Track, RMAT and Rare Pediatric Disease designations from FDA.

antibody deplete program

Stage not disclosed · Active Modality: antibody

Indications

ATTR-CM (Stage not disclosed)

Status note Company references a new antibody deplete program for ATTR-CM; clinical timeline referenced in filing but no named candidate or stage stated.

Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	infigratinib 0.128 mg/kg/day
Lead indication	Hypochondroplasia
Lead phase	Phase 3
Active trials	14
Collaborator trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06873035	Phase 3	Enrolling by invitation	Sponsor	BBIO	—	Hypochondroplasia	—
NCT07805356	Phase 3	Not yet recruiting	Sponsor	BBIO	—	Hypoparathyroidism; Chronic Hypoparathyroidism	—
NCT04988386	Phase 3	Active, not recruiting	Sponsor	BBIO	—	Amyloid Cardiomyopathy, Transthyretin-Related	—
NCT07080385	Phase 3	Recruiting	Sponsor	BBIO	—	Autosomal Dominant Hypocalcemia Type 1 (ADH1)	—
NCT06563895	Phase 3	Recruiting	Sponsor	BBIO	—	Amyloidosis; Amyloid Cardiomyopathy; Transthyretin Amyloidosis	—
NCT07116473	Phase 3	Not yet recruiting	Sponsor	BBIO	—	Amyloidosis in Transthyretin (TTR); Amyloidosis, Familial; Amyloid Cardiomyopathy	—
NCT05680818	Phase 3	Active, not recruiting	Sponsor	BBIO	—	Autosomal Dominant Hypocalcemia (ADH)	—
NCT03536767	Phase 2	Active, not recruiting	Sponsor	BBIO	—	Amyloid Cardiomyopathy	—
NCT07169279	Phase 2	Recruiting	Sponsor	BBIO	—	Achondroplasia	—
NCT05145010	Phase 2	Enrolling by invitation	Sponsor	BBIO	—	Achondroplasia	—
NCT07393373	Phase 2	Enrolling by invitation	Sponsor	BBIO	—	Hypochondroplasia	2H 2026
NCT06410976	Not disclosed	Recruiting	Sponsor	BBIO	—	Hypochondroplasia	—

Sponsor-matched active trials from ClinicalTrials.gov (14 as sponsor, 3 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 17 active trials for QED Therapeutics, a BridgeBio company on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Frazier Life Sciences	1,548,139	-1,900,000	2.51%	2026-08-14
ADAR1 Capital Management	271,689	+82,397	1.25%	2026-08-14
Sphera Biotech	245,346	+100	2.61%	2026-08-14
Ikarian Capital	57,417	-102,703	0.70%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

BBIO — BridgeBio Pharma Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders